Speaker Biographies

Monica is a Director of Global Alliances at Bristol Myers Squibb, where she has over a decade of experience in the pharmaceutical industry. Known for her people-centered approach to managing collaborations, Monica excels at navigating complex relationships, building trust, and enhancing teamwork, both internally and externally. Her background as a pharmacist and business leader allows her to offer a uniquely strategic perspective to her alliances, fostering robust stakeholder relationships within the ever-evolving landscape of organizational structures and industry dynamics. Beyond her professional achievements, Monica is deeply committed to giving back to the community, mentoring STEM students at local universities, as well as PharmD fellows and interns. She brings to her role both a PharmD and an MBA from Rutgers University and completed a two-year fellowship at Celgene in Medical Affairs Hematology/Oncology.

Matt Brosnan is a Director of Global R&D Alliance Management with experience supporting global partnerships across clinical-stage immunology, inflammatory, and gastroenterology programs. His work focuses on strengthening collaboration between Global Program Leaders and Alliance Managers to enable aligned planning, clear governance, and effective decision-making with partners. Matt has led alliances spanning discovery through late clinical development and works closely with cross-functional teams to navigate strategic priorities, operational interfaces, and joint governance structures. He holds an MBA from Babson College with a concentration in entrepreneurial leadership and organizational strategy. He is committed to building partnership-first environments that support transparency, shared accountability, and progress toward meaningful outcomes for patients.

Judy Campagnari, MBA is Executive Director, Head of Alliance & Integration Management at Alexion, AstraZeneca Rare Disease. Her team oversees the coordination, execution, management, and success of Alexion’s acquisitions, collaborations, and alliances. Over her 30 years in the pharmaceutical industry Judy has developed an expertise in creating commercial value from research vision. She has extensive experience managing the commercial strategy for both internally developed as well as partnered programs from the pre-clinical/discovery phase through proof of concept, including Tarceva® (erlotinib), Xeljanz® (tofacitinib), and Eliquis® (apixaban; Pfizer co-promote with BMS). She has broad therapeutic & disease area expertise including rare disease, neurology, metabolic diseases, bone diseases, gastrointestinal diseases, immunology, and oncology. Judy has a bachelor’s degree from Smith College (Northampton, MA), an MBA from the Katz Graduate School of Business/University of Pittsburgh, and an Executive MBA Certificate from the Harvard Business School.

Karen is the Director of Oncology R&D Alliance Management at AstraZeneca. Over the past eight years, she has led the management of global corporate partnerships for portfolio assets across AstraZeneca, overseeing high-impact collaborations that span research and clinical development. Her expertise includes leading cross-functional transition teams for mergers and acquisitions and launching and managing strategic partnerships across Oncology and other therapeutic areas at multiple stages of development. With more than 20 years of experience in the biopharmaceutical industry, Karen began her career as an Oncology Scientist at MedImmune, AstraZeneca’s former biologics division, before transitioning into alliance management. She holds a Master of Science in Clinical Sciences from Purdue University and maintains professional certifications as a Project Management Professional (PMP) and Certified Alliance Manager (CA-AM).

Working in the biotech/pharma sector over the last 20 years, my career has evolved from technical roles in the lab to operational and program leadership, finally finding my perfect niche in alliance management. I've worked at a number of start-up and smaller biotech companies including Codon Devices, RainDance Technologies, Trek Therapeutics, and TESARO, as well as roles in pharma including Vertex, Genzyme, and GSK. I've been at GSK for 5 years and have enjoyed the experience to work on a wide range of partnerships and expand my team in the Boston area.

Andi is a business-savvy people person executive with 15+ years of alliance management experience and proven abilities in leadership and global expansion in biotech, pharma, and life sciences. She is multilingual and experienced in managing geographically diverse partners (Asia, Europe, the Americas, and the Middle East). Peer influencer who skillfully negotiates contract terms and operationalizes contracts that represent cross-functional interests within organizations, and who is talented in translating analytical insights into succinct, actionable strategies. At Biogen, she implements, manages, and optimizes complex multiprogram alliances globally. Among others, she previously served as a member of an integration team for Lilly’s acquisition of Dermira and held other alliance management positions at Jazz Pharmaceuticals and Color, as well as in other roles at Amgen, Lonza, and Cambrex. Andi has a great interest in collaboration and partnership, she is a pharmacist by training and holds an MBA from Pepperdine University.

Julia Gershkovich, Alliance Management Business Partner for the North America Hub at Sanofi, has over 25 years of Biotech/ Pharma experience in alliance management and product development in the healthcare industry. She held positions with broad range of responsibilities in general management, marketing, business development and program management. Julia has a long track record in managing complex alliances and high performance cross-functional global teams across different therapeutic areas, technology platforms and organizational structures. Julia is a frequent invited speaker at conferences and is the author of multiple scientific publications. Julia received an MS in polymer science from Chemical Technological University of Russia and did a doctorate study in polymer chemistry at GIPI LPC / Instititute of Physical Chemistry, Academy of Sciences in Moscow, Russia

Sam is a seasoned leader in alliance management and customer relationship oversight within the pharmaceutical industry, with over a decade of progressive experience. Currently serving as Senior Director, Global Alliances at Bristol Myers Squibb, Sam has spearheaded multi-billion dollar partnerships, streamlined governance processes, and influenced successful negotiations and acquisitions. Her expertise spans fostering operational excellence, mentoring cross-functional teams, and driving strategic alignment between global stakeholders. Previously, Samantha held pivotal roles at Covance Central Laboratory Services, where she oversaw major alliances and led a global project management team, consistently delivering results for top-tier accounts. Recognized for her ability to resolve complex challenges and motivate teams, Sam’s leadership has been instrumental in optimizing performance and cultivating robust stakeholder relationships across matrixed environments.

Patrick Gliha is Vice President, Strategic Alliance Leadership & Management at Flagship Pioneering, leading the team responsible for managing and advancing Flagship’s strategic alliances with partners including GSK, Pfizer, Novo Nordisk, and Evotec. In this role, Patrick oversees alliance execution and program development that drive scientific innovation and enterprise value across the Flagship ecosystem. Before joining Flagship, Patrick was Executive Director at Bristol Myers Squibb (BMS), where he led a global team of alliance leaders and managed a diverse portfolio of strategic partnerships from early discovery through commercialization. He also oversaw BMS’s Asia-Pacific alliance portfolio, deepening the company’s strategic alliances in high-priority markets such as Japan and China. Patrick’s career includes leadership roles at Celgene and Amgen, where he built and led high-performing teams in multiple functions. Patrick received his MBA from Ohio University and his B.A. from The University of Akron.

Driving Global Success in Rare Disease and RNAi Biotech Partnerships. Samuel Gosselin is a seasoned Alliance Management leader with over 20 years of global experience in the biotech and CRO sectors. Since October 2025, he has served asn Head of Alliance Management at SanegeneBio, an RNAi-focused company advancing next-generation therapeutics through its LEAD™ platform. He brings strong leadership and a broad functional understanding that enable effective collaboration management with large pharma partners. Previously, at Sarepta, Biogen, and Marinus Pharmaceuticals, Samuel built and scaled Alliance Management functions from the ground up, supporting programs from early development through global launch. A CA-AM–certified professional and MBA graduate, Samuel is a frequent ASAP speaker, white paper contributor, and advocate for elevating Alliance Management as a strategic function in biotech partnerships.

Kimberly E. Koch is a Senior Director of Alliance and Innovation Management at Eli Lilly and Company, where she has demonstrated exceptional leadership in managing some of the company's most strategic and complex partnerships. Kim is recognized both internally and externally as a leading expert in alliance management, is regularly sought after to resolve high-impact issues and to drive positive outcomes in challenging alliance environments. Throughout her career, Kim has led corporate-level governance for major strategic alliances, successfully navigating significant business events including alliance restructurings, global launches, and complex contract negotiations that have realized substantial value. Her expertise spans the full spectrum of alliance management, including governance excellence, relationship management, risk mitigation, and cross-functional leadership. Kim is deeply committed to advancing the alliance management profession-she has developed and taught training courses, co-facilitated full-day workshops, served on conference panels, and co-authored publications including the book Creating Alliance Value. She has also delivered alliance management training internationally, working with teams across Asia, Latin America, and North America to build capabilities and share best practices. Kim is known for her inclusive leadership style, strategic thinking, and ability to drive results through collaboration.

Bridget is a senior conference director with over 20 years of experience in development, production and marketing of educational networking conferences across multiple industries, geographies, and cultures. Currently, she focuses on connecting biopharma leaders to advance pharmaceutical R&D in clinical trial operations, alliance management, data science and informatics, and program, portfolio and resource management.

Dr. Emma Lees holds a PhD from Imperial Cancer Research Fund, London England and performed post-doctoral work for Cold Spring Harbor labs and Harvard Medical school, Massachusetts General Hospital Cancer Center. Her industry career began at DNAX Research Institute/Schering Plough in Palo Alto, California, where she was responsible for building and leading the Oncology Research group. From there, Emma joined Novartis Institutes of Biomedical Research (NIBR) as Site Head and Vice President of Oncology in Emeryville, California, and later became Vice President of Oncology Biotherapeutics in Cambridge, Massachusetts, where she was responsible for the design, development and strategy and implementation of the biologic’s oncology portfolio. Emma transitioned to Jounce Therapeutics, also in Cambridge, a small immuno-oncology company where she served as Head of Research. Presently, Emma is Senior Vice President, Oncology Discovery at Bristol Myers Squibb and serves as Site Head at Bristol Myers Squibb’s Cambridge, MA location. Emma’s team is primarily focusing on understanding resistance to standard of care therapies, studying patients who do not respond or build resistance to current drugs, with a goal to discover medicines for these patients’ populations with unmet medical needs. In her role as Site Head, Emma collaborates with the site leadership team to craft a unified vision, set objectives, and cultivate culture that aligns with the global strategy.

Dynamic, results-driven professional with over 25 years of experience in alliance management, business development, and engineering within the pharmaceutical industry. Demonstrated success in driving global strategic collaborations in oncology, co-commercializing products across more than 25 markets. Ken earned a BS in Engineering from the University of Pennsylvania and a Masters degree in Technology Management from Stevens Institute of Technology. He is a licensed Professional Engineer (inactive), a Certified Licensing Professional, and holds a Certificate of Achievement in Alliance Management.

Amanda McAllister is a Global Alliance Leader at AbbVie with responsibility for AbbVie's collaborations with cross therapeutic platform technology, neurotoxins, and Allergan Aesthetics. She is an energetic and creative strategist, who inspires teams to move forward innovatively. She helps drive positive transformation by creating a collaborative and inclusive environment. Amanda has over 15 years of experience in pharma with roles spanning across supply chain, logistics, program management for all phases of drug development, commercialization, and alliance management. She’s passionate about challenging norms to make things better and, ultimately, changing people's lives in a positive and meaningful way.

Sharon is a senior level executive in the biopharmaceutical industry and joined Alloy Therapeutics in April 2025 to manage the Genetic Medicines’ alliances with biopharma partners, starting with the Sanofi partnership, and to establish the Alliance Management function. Previously, Sharon was Executive Director, Alliance Management at Fulcrum Therapeutics where she managed collaborations with Sanofi and BMS. Prior to that, Sharon was Executive Director, Head of Alliance Management at AffaMed Therapeutics, where she managed 10 partnerships for 19 in-licensed assets, and established the Alliance Management function and Best Practices. Prior to joining AffaMed in 2021, Sharon was Director, Global Alliance Management at Sanofi. Overall, Sharon has managed 26 Research, Development, and Commercial stage partnerships across a wide range of therapeutic areas, and with large pharmaceutical, small biotech, and digital therapeutics companies, with academic institutions, and for joint ventures. Sharon has spoken about her Alliance Management experiences at several Alliance Management and partnering conferences and she has also been interviewed for Alliance Management publications. Before transitioning to Alliance Management, Sharon held positions of increasing responsibility as a pre-clinical research scientist at Genzyme and Sanofi. During that time, Sharon led numerous project teams, focus groups, and External Innovation activities, and participated in, established, and managed several research collaborations. Sharon earned a B.S. in Molecular Genetics from the University of Rochester, a Ph.D. in Biology from the Albert Einstein College of Medicine, and CA-AM certification from the Association of Strategic Alliance Professionals (ASAP).

Beth Odeh-Frikert is the Head of Global Alliance and Asset Management in Pharma Partnering at Genentech. Beth received her Doctorate of Pharmacy degree from the University of Michigan and completed a 2-year post-doctoral fellowship at Roche and Genentech, followed by an executive business program through INSEAD. During her 25-year career at Roche and Genentech, Beth has held key leadership positions across all phases of drug development and commercialization. Through her career, she has led global teams within Partnering, Product Development, Medical, Commercial and Manufacturing organizations. In her current role, Beth leads with a passion for science and a commitment to bring innovative medicines to patients through partnerships.

Claire joined the Alliance Management team at Amgen in 2024. Claire manages Amgen’s in-license portfolio and multiple late-stage and commercial alliances. Prior to joining Amgen, she worked at PricewaterhouseCoopers (PwC) in the Deals practice. Claire received a Bachelor’s in Risk Management and Insurance from Temple University’s Fox School of Business.

Brian is an Associate Director of Strategic Alliances at Click Therapeutics. Click and its biopharma partners are redefining medicine with patient-centric digital treatments, and Brian is responsible for the overall health and strategic vision of these alliances. Brian's previous alliance experience includes Partnerships Lead for the UM International Investment Fund and Portfolio Success Lead for Booz Allen Ventures. He is a recovering startup banker and has degrees from the University of Notre Dame and the Michigan Ross School of Business.

Jason Powell is Senior Director of Global Alliances at AbbVie, where he has built a nearly 30-year career spanning commercial leadership, sales management, U.S. and international marketing, business development, and alliance management. Over the past 15 years, Jason has specialized in managing complex global collaborations across all stages of development, with a particular emphasis on late-stage and on-market assets. He is recognized for his ability to navigate large, multi-stakeholder partnerships and deliver sustainable value through strategic collaboration. Jason brings deep experience in alliance governance, operational execution, and building trusted partnerships that drive mutual success. Outside of work, Jason is a proud father of six and grandfather of one (with another on the way), and he enjoys traveling, outdoor activities, and time with his family.

Executive Director, Business and Alliance Management, Moderna

Mr. Sanburn is the Chief Business Officer at Verastem Oncology with nearly 30 years of experience across discovery, clinical development, portfolio strategy, business development, and collaborations. Since joining Verastem in 2022, Mr. Sanburn has played key roles in strategic business development and external engagement initiatives, supporting alliance management, clinical operations, and field medical functions. His leadership has been instrumental in securing Verastem’s exclusive rights to avutometinib in the EU and Japan, receiving the inaugural PanCan Therapeutic Accelerator Award, establishing a discovery and development agreement with GenFleet for multiple RAS pathway-targeted programs, and facilitating a strategic commercial collaboration with IQVIA for the launch of AVMAPKI™ FAKZYNJA™ CO-PACK. Prior to Verastem, Mr. Sanburn served for more than 20 years in multiple scientific, clinical, and business leadership roles at Eli Lilly and Company where he owned key responsibilities across key licensing deals, research and development collaborations, clinical trial agreements, and strategic pharma and biotech transactions, including the acquisitions of Imclone and Loxo Oncology. He initiated Lilly’s collaboration with Merck on the KEYNOTE-189 trial (KEYTRUDA® plus Alimta® and platin) leading to subsequent cross-promotional activities for Alimta® and Lilly’s collaboration with AstraZeneca for cross label promotion of Verzenio® plus Faslodex® . Earlier in his career, Mr. Sanburn helped establish the National Gene Vector Laboratory at Indiana University Medical Center, which played a significant role in advancing some of the earliest clinical development programs for gene therapies. Mr. Sanburn received his undergraduate degree from Indiana University and his graduate degree from Purdue University.

Anna Skabeev, MD, MBA, CA-AM is Senior Director of Alliance Management at Teva Pharmaceuticals, where she leads a global portfolio of strategic alliances and integration initiatives. With deep expertise in navigating complex partnerships across the biopharma landscape, Anna brings a cross-functional lens to alliance execution, value creation, and post-deal integration. Prior to joining Teva, Anna held a similar role at Karyopharm Therapeutics and earlier built a diverse foundation across Commercial and Clinical Development functions at Biogen, Alkermes, Ironwood, and Sanofi—supporting programs and brands throughout their lifecycle. Anna earned her MD from the St. Petersburg Pediatric Medical Academy in Russia and her MBA from Suffolk University in Boston. She is a Certified Alliance Management professional (CA-AM) and a contributor to industry forums. Anna lives in Newton, MA with her family.

Dr. Ashley Snyder holds a PharmD from University of Colorado, and performed her post-doctoral work while receiving a masters in public health from Wayne State University in Detroit. Her industry career began at Merck in the infectious diseases and vaccines division where she was a Research Scientific Director and focused on filling data gaps in the pipeline through investigator sponsored studies, while providing scientific information and education to academic institutions. While there, she did a secondment in BD&L with the West Coast Innovation Hub. From there, she joined Sangamo Therapeutics as a Clinical Scientist to deepen her clinical development expertise and then pivoted into Alliance Management. Ashley transitioned to Vir Bio, also in San Francisco, a small infectious disease company where she led the alliance between GSK for the next-gen Covid antibody and the Covid vaccine collaboration, among other governmental partnerships. Presently, Ashley is Senior Director, Alliance Management at Everest Medicines, leading partnerships between US biotech and products in-licensed for co-development in China. She is based in Nashville, TN.

Peggy is Vice President and Head of Alliance Management at Alnylam where she leads a team responsible for ensuring the successful launch and execution of the company’s various partnerships in all stages of the drug development and commercialization lifecycle. She has over 20 years’ experience in the life science and biotech industry. Peggy holds an ScD in Cell Biology from Harvard University and started her career as a scientist. In subsequent roles, she developed broad leadership and business expertise, including experience in M&A. Prior to joining Alnylam in 2020, Peggy was the General Manager of the Neuroscience business unit at BioLegend.

Jan Twombly, CSAP, is president of The Rhythm of Business, a consultancy and training firm with expertise in partnering, alliances, and collaboration. For over 20 years, she has been a leader in advancing the practice of alliance management. Current emphasis is on ensuring alliance professionals deliver the services of greatest value to stakeholders and digitizing its workflow. She serves on the Board of Directors of the Association of Strategic Alliance Professionals.

With over 25 years of experience in Life Sciences, Doug specializes in cultivating strategic alliances within the Biotechnology and Pharmaceutical sectors. As an expert in driving innovation, maximizing value, and mitigating risk across diverse alliance portfolios, Doug has consistently delivered measurable results throughout his career. Known for fostering trust among diverse stakeholders, Doug's extensive collaboration experience spans the entire spectrum from research and development to commercialization. His proven track record in these areas underscores his dedication to advancing the field and achieving impactful outcomes. In addition to his expertise in life sciences, Doug has a growing interest in artificial intelligence. He is dedicated to building upon his foundation of knowledge in AI to further enhance strategic decision-making and optimize alliance management. His commitment to continuous learning reflects Doug's desire to be at the forefront of industry innovation.